CONCLUSION
A three state partitioned survival model was developed over a 30 year time horizon (Figure 1). Movement between health states was determined by progression-free survival (PFS) and overall survival (OS) data using interim results from KEYNOTE-002 (KN-002). KN-002 is a Phase II randomised controlled clinical trial comparing pembrolizumab to investigators choice of chemotherapy in patients progressing after treatment with ipilimumab and a BRAF or MEK inhibitor (if tested positive for the BRAFv600 mutation).
A two part curve fit was applied to the PFS for the pembrolizumab arm: 1. Kaplan-Meier (KM) curves were used until Week 13 at which point all patients should have received their first scan; 2. A Gompertz parametric curve fit after this. In the case of the chemotherapy arm the PFS curve showed that the number of patients that are progression-free and alive was approximately 0% at the end of the trial so just KM data were used. The OS data in KN002 and the atypical survival profiles for immunotherapies in clinical practice suggested that it was inappropriate to use a standard parametric curve fit based only upon within trial data to extrapolate long-term survival. A three part curve was used for the pembrolizumab arm: 1. KM data from the KN-002 trial were used for the duration of available reliable data (one year); 2. A curve which consists of long-term ipilimumab survival data for previously treated patients 1 for the duration of observed survival (1-10 years); 3. Melanoma survival registry data 2 plus general population mortality data 3 (>10 years) This method assumes that all patients that survive up to one year in the pembrolizumab trial have the same future survival prospects (conditional survival probability) as was seen in the ipilimumab trials until the limit of available data; they also have similar survival to historical advanced melanoma patients who lived to 10 years treated with chemotherapy. Probabilistic sensitivity analysis showed some uncertainty around costs and QALYs (probabilistic incremental cost-effectiveness ratio [ICER] = £67,615). This is due to the uncertainty in the relatively short-term PFS data from the KN-002 clinical trial, meaning that in some samples a substantial proportion of patients are being treated for 20 years or more, with it being unlikely that patients surviving in the long term will be treated for life. The cost-effectiveness acceptability curve (CEAC) (Figure 3a) shows that there is an approximately 50% chance of pembrolizumab being cost effective when compared to BSC at the £50,000 per QALY threshold. When the treatment duration was limited to 24 months, the uncertainty in the probabilistic results was greatly reduced. With the treatment duration limitation applied to the model the deterministic ICER was £31,764 and the probabilistic mean ICER was £33,841. The CEAC when considering this treatment limitation (Figure 4) indicates an 87% chance of pembrolizumab being cost effective at the £50,000 per QALY threshold.
One-way sensitivity analysis showed the input that most affects the ICER is the curve fit parameters assumed for PFS.
In TA268 4 the resource use data was sourced from the MELODY 5 study. This was still considered to be the most appropriate source for resource data for pembrolizumab as there were no other alternative sources identified from an economic literature review. Patient weight distributions from the KN-002 clinical trial were used to calculate that the average number of 50mg pembrolizumab vials required per patient per dose was 3.6. The dosing schedule for BSC was taken from the ipilimumab second-line NICE submission (TA268) 4 . The mean body surface area from the KN-002 trial was used to calculate the required dosing for BSC. Monthly Index of Medical Specialties (MIMS) 6 and Drugs and pharmaceutical electronic market information (eMit) 7 were used to obtain drug costs for the intravenous (IV) chemotherapies which make up best supportive care which are all delivered via IV complex chemotherapy administration as has been reported in previous submissions for metastatic melanoma. In the base case pembrolizumab is administered as simple chemotherapy as administration takes less than 30 minutes; this was considered to be most appropriate by clinicians. Administration costs and resource use costs were sourced from National Health Service (NHS) reference costs 8 and from the PSSRU 2014. 9 The cost of terminal care was sourced from Georghiou & Bardsley (2014). 10 Due to the high level of crossover in the trial (86/179 on the control arm), presentation of an intent-to-treat analysis for overall survival is inappropriate. In accordance with NICE Decision Support Unit guidance, the two-stage method was selected for adjustment in the model base case, as crossover occurred within the trial upon progression (hazard ratio (HR) = 0.63). Two alternative methods were tested; inverse probability of censoring weighting (IPCW) (HR=0.68), although this method is limited due to low sample size and high percentage crossover and rank-preserving structural failure time (RPSFT), which was deemed inappropriate as equal efficacy pre-and post-progression could not be safely assumed. £10,000 £20,000 £30,000 £40,000 £50,000 £60,000 £70,000 £80,000 £90,000 £100,000
Willingness-to pay threshold Probability that intervention is cost-effective Comparator  Pembrolizumab   100%   90%   80%   70%   60%   50%   40%   30%   20%   10%   0%   £0 £10,000 £20,000 £30,000 £40,000 £50,000 £60,000 £70,000 £80,000 £90,000 £100,000
Willingness-to pay threshold Probability that intervention is cost-effective 
